BACKGROUND: Although known as a rare adverse drug reaction (ADR), drug fever (DF) remains an important issue in medicine, with the risk of leading to inappropriate and potentially harmful diagnostic and therapeutic interventions. Only sparse data regarding DF have been published. OBJECTIVE: The aim of the study was to investigate which drugs were associated with DF, and report outcomes. METHODS: Cases of DF without skin reactions were selected from all ADRs reported from 1986 to 2007 in the French National Pharmacovigilance Database. Drugs potentially responsible for DF were assessed using a qualitative case-by-case analysis (Naranjo's criteria) and quantitative measurement (proportional reporting ratio [PRR]). A drug was implicated as the cause of DF when the following criteria were validated: three or more cases and PRR of at least two with a Chi-squared value of at least four. RESULTS: A total of 167 DF cases involving 115 drugs were eligible. Based on the PRR, 22 drugs were significantly associated with DF. Antibacterials represented the most frequently reported drugs, including amikacin (PRR 39.6 [95% CI 23.6, 69.0], oxacillin (9.1 [3.6, 23.4]), cefotaxime (5.5 [2.0, 15.3]), ceftriaxone (5.4 [2.6, 11.3]), rifampicin (4.0 [1.8, 9.2]), vancomycin (4.0 [1.4, 11.5]), ciprofloxacin (3.1 [1.2, 8.0]), isoniazid (3.9 [1.4, 11.4]), pristinamycin (3.1 [1.0, 9.1]) and cotrimoxazole (2.6 [1.2, 5.8]). Median time [interquartile range] from drug administration to fever onset was 2 days [1.0-10.5]. A diagnosis of DF was made following cessation of the suspected drugs (3 days [1.0-11.5] after fever onset. Drug rechallenge was performed (38.0%), resulting in recurrence of DF in all cases. DF resulted in life-threatening events (0.6%), hospitalization or prolonged hospital stay (24.5%) and persistent disability (0.6%). Final outcome was favourable in 96.9% of cases after drug discontinuation. CONCLUSION: Diagnosing DF is challenging. Based on this large series, antibacterials remain the major class of drugs responsible for DF.
BACKGROUND: Although known as a rare adverse drug reaction (ADR), drug fever (DF) remains an important issue in medicine, with the risk of leading to inappropriate and potentially harmful diagnostic and therapeutic interventions. Only sparse data regarding DF have been published. OBJECTIVE: The aim of the study was to investigate which drugs were associated with DF, and report outcomes. METHODS: Cases of DF without skin reactions were selected from all ADRs reported from 1986 to 2007 in the French National Pharmacovigilance Database. Drugs potentially responsible for DF were assessed using a qualitative case-by-case analysis (Naranjo's criteria) and quantitative measurement (proportional reporting ratio [PRR]). A drug was implicated as the cause of DF when the following criteria were validated: three or more cases and PRR of at least two with a Chi-squared value of at least four. RESULTS: A total of 167 DF cases involving 115 drugs were eligible. Based on the PRR, 22 drugs were significantly associated with DF. Antibacterials represented the most frequently reported drugs, including amikacin (PRR 39.6 [95% CI 23.6, 69.0], oxacillin (9.1 [3.6, 23.4]), cefotaxime (5.5 [2.0, 15.3]), ceftriaxone (5.4 [2.6, 11.3]), rifampicin (4.0 [1.8, 9.2]), vancomycin (4.0 [1.4, 11.5]), ciprofloxacin (3.1 [1.2, 8.0]), isoniazid (3.9 [1.4, 11.4]), pristinamycin (3.1 [1.0, 9.1]) and cotrimoxazole (2.6 [1.2, 5.8]). Median time [interquartile range] from drug administration to fever onset was 2 days [1.0-10.5]. A diagnosis of DF was made following cessation of the suspected drugs (3 days [1.0-11.5] after fever onset. Drug rechallenge was performed (38.0%), resulting in recurrence of DF in all cases. DF resulted in life-threatening events (0.6%), hospitalization or prolonged hospital stay (24.5%) and persistent disability (0.6%). Final outcome was favourable in 96.9% of cases after drug discontinuation. CONCLUSION: Diagnosing DF is challenging. Based on this large series, antibacterials remain the major class of drugs responsible for DF.
Authors: Nese Saltoglu; Yesim Tasova; Durdane Midikli; Hasan S Z Aksu; Aslihan Sanli; Ismail H Dündar Journal: J Infect Date: 2004-01 Impact factor: 6.072
Authors: F J Barbado; J Gómez-Cerezo; J M Peña; M C Garcés; A Barbado-Cano; J J Ríos; M I González-Anglada; F Arnalich; J J Vázquez Journal: J Med Date: 2001
Authors: Cyndie K Mannesse; Eugène P van Puijenbroek; Paul A F Jansen; Rob J van Marum; Patrick C Souverein; Toine C G Egberts Journal: Drug Saf Date: 2010-07-01 Impact factor: 5.606
Authors: L S Elting; E B Rubenstein; D Kurtin; K V Rolston; J Fangtang; C G Martin; I I Raad; E E Whimbey; E Manzullo; G P Bodey Journal: Cancer Date: 1998-12-15 Impact factor: 6.860
Authors: Mario Sánchez-Borges; Bernard Thong; Miguel Blanca; Luis Felipe Chiaverini Ensina; Sandra González-Díaz; Paul A Greenberger; Edgardo Jares; Young-Koo Jee; Luciana Kase-Tanno; David Khan; Jung-Won Park; Werner Pichler; Antonino Romano; Maria José Torres Jaén Journal: World Allergy Organ J Date: 2013-10-31 Impact factor: 4.084